Helmuth Haslacher
Hivatkozott rá
Hivatkozott rá
Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score
MM Schoels, D Aletaha, F Alasti, JS Smolen
Annals of the rheumatic diseases 75 (5), 811-818, 2016
Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease
G Slavka, T Perkmann, H Haslacher, S Greisenegger, C Marsik, ...
Arteriosclerosis, thrombosis, and vascular biology 31 (5), 1215-1218, 2011
A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection
F Eskandary, H Regele, L Baumann, G Bond, N Kozakowski, ...
Journal of the American Society of Nephrology 29 (2), 591-605, 2018
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity
D Mrak, S Tobudic, M Koblischke, M Graninger, H Radner, D Sieghart, ...
Annals of the rheumatic diseases 80 (10), 1345-1350, 2021
Anti-spike protein assays to determine SARS-CoV-2 antibody levels: a head-to-head comparison of five quantitative assays
T Perkmann, N Perkmann-Nagele, T Koller, P Mucher, A Radakovics, ...
Microbiology spectrum 9 (1), e00247-21, 2021
Side-by-side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity
T Perkmann, N Perkmann-Nagele, MK Breyer, R Breyer-Kohansal, ...
Clinical Chemistry 66 (11), 1405-1413, 2020
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response
MM Bonelli, D Mrak, T Perkmann, H Haslacher, D Aletaha
Annals of the rheumatic diseases 80 (10), 1355-1356, 2021
Azithromycin suppresses CD4+ T-cell activation by direct modulation of mTOR activity
F Ratzinger, H Haslacher, W Poeppl, G Hoermann, JJ Kovarik, S Jutz, ...
Scientific reports 4 (1), 1-10, 2014
Additive gene–environment effects on hippocampal structure in healthy humans
U Rabl, BM Meyer, K Diers, L Bartova, A Berger, D Mandorfer, A Popovic, ...
Journal of Neuroscience 34 (30), 9917-9926, 2014
Utility of sepsis biomarkers and the infection probability score to discriminate sepsis and systemic inflammatory response syndrome in standard care patients
F Ratzinger, M Schuardt, K Eichbichler, I Tsirkinidou, M Bauer, ...
PloS one 8 (12), e82946, 2013
Usage data and scientific impact of the prospectively established fluid bioresources at the hospital-based MedUni Wien Biobank
H Haslacher, M Gerner, P Hofer, A Jurkowitsch, J Hainfellner, R Kain, ...
Biopreservation and biobanking 16 (6), 477-482, 2018
Diagnostic contribution of donor-specific antibody characteristics to uncover late silent antibody-mediated rejection—results of a cross-sectional screening study
F Eskandary, G Bond, N Kozakowski, H Regele, L Marinova, ...
Transplantation 101 (3), 631-641, 2017
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
R Bartsch, AS Berghoff, J Furtner, M Marhold, ES Bergen, S Roider-Schur, ...
Nature Medicine 28 (9), 1840-1847, 2022
Determination of autoantibody isotypes increases the sensitivity of serodiagnostics in rheumatoid arthritis
D Sieghart, A Platzer, P Studenic, F Alasti, M Grundhuber, S Swiniarski, ...
Frontiers in Immunology 9, 876, 2018
Pilot PET study to assess the functional interplay between ABCB1 and ABCG2 at the human blood–brain barrier
M Bauer, K Römermann, R Karch, B Wulkersdorfer, J Stanek, C Philippe, ...
Clinical Pharmacology & Therapeutics 100 (2), 131-141, 2016
Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood–brain barrier
M Bauer, R Karch, M Zeitlinger, J Stanek, C Philippe, W Wadsak, ...
Journal of Nuclear Medicine 54 (8), 1181-1187, 2013
CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection
K Doberer, J Kläger, GA Gualdoni, KA Mayer, F Eskandary, EA Farkash, ...
Transplantation 105 (2), 451-457, 2021
Cognitive function in elderly marathon runners: cross-sectional data from the marathon trial (APSOEM)
R Winker, I Lukas, T Perkmann, H Haslacher, E Ponocny, J Lehrner, ...
Wiener Klinische Wochenschrift 122, 704-716, 2010
Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial
F Eskandary, G Bond, E Schwaiger, Z Kikic, C Winzer, M Wahrmann, ...
Trials 15, 1-9, 2014
Humoral immune response in hematooncological patients and health care workers who received SARS-CoV-2 vaccinations
MJ Mair, JM Berger, AS Berghoff, AM Starzer, G Ortmayr, HC Puhr, ...
JAMA oncology 8 (1), 106-113, 2022
A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.
Cikkek 1–20